File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: STAT3 as a therapeutic target in head and neck cancer

TitleSTAT3 as a therapeutic target in head and neck cancer
Authors
KeywordsHead and neck cancer
STAT3 inhibitors
STAT3 targeted therapy
Issue Date2006
Citation
Expert Opinion on Biological Therapy, 2006, v. 6 n. 3, p. 231-241 How to Cite?
AbstractThe signal transducer and activator of transcription (STAT) proteins relay signals from cytokine receptors and receptor tyrosine kinases on the cell surface to the nucleus, where they affect the transcription of genes involved in normal cell functions, including growth, apoptosis and differentiation. STAT3 has been found to be constitutively active in head and neck squamous cell carcinoma (HNSCC) as well as in other epithelial malignancies. In HNSCC, STAT3 alters the cell cycle, prevents apoptosis, and mediates the proliferation and survival of tumour cells. Several therapeutic approaches are being developed to target STAT3, including molecules that block either dimerisation or DNA binding by STAT3, strategies to decrease STAT3 expression and drugs that inhibit STAT3 function. Strategies that block STAT3 may prove efficacious for cancer treatment. © 2006 Ashley Publications.
Persistent Identifierhttp://hdl.handle.net/10722/194157
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.104
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeeman, RJ-
dc.contributor.authorLui, VWY-
dc.contributor.authorGrandis, JR-
dc.date.accessioned2014-01-30T03:32:14Z-
dc.date.available2014-01-30T03:32:14Z-
dc.date.issued2006-
dc.identifier.citationExpert Opinion on Biological Therapy, 2006, v. 6 n. 3, p. 231-241-
dc.identifier.issn1471-2598-
dc.identifier.urihttp://hdl.handle.net/10722/194157-
dc.description.abstractThe signal transducer and activator of transcription (STAT) proteins relay signals from cytokine receptors and receptor tyrosine kinases on the cell surface to the nucleus, where they affect the transcription of genes involved in normal cell functions, including growth, apoptosis and differentiation. STAT3 has been found to be constitutively active in head and neck squamous cell carcinoma (HNSCC) as well as in other epithelial malignancies. In HNSCC, STAT3 alters the cell cycle, prevents apoptosis, and mediates the proliferation and survival of tumour cells. Several therapeutic approaches are being developed to target STAT3, including molecules that block either dimerisation or DNA binding by STAT3, strategies to decrease STAT3 expression and drugs that inhibit STAT3 function. Strategies that block STAT3 may prove efficacious for cancer treatment. © 2006 Ashley Publications.-
dc.languageeng-
dc.relation.ispartofExpert Opinion on Biological Therapy-
dc.subjectHead and neck cancer-
dc.subjectSTAT3 inhibitors-
dc.subjectSTAT3 targeted therapy-
dc.titleSTAT3 as a therapeutic target in head and neck cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14712598.6.3.231-
dc.identifier.pmid16503733-
dc.identifier.scopuseid_2-s2.0-33644773438-
dc.identifier.volume6-
dc.identifier.issue3-
dc.identifier.spage231-
dc.identifier.epage241-
dc.identifier.isiWOS:000235984100004-
dc.identifier.issnl1471-2598-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats